James J Saller
Overview
Explore the profile of James J Saller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saeed-Vafa D, Chatzopoulos K, Hernandez-Prera J, Cano P, Saller J, Hallanger Johnson J, et al.
Front Genet
. 2024 Apr;
15:1377158.
PMID: 38566816
Medullary thyroid carcinoma (MTC) is an aggressive cancer that is often caused by driver mutations in . Splice site variants (SSV) reflect changes in mRNA processing, which may alter protein...
2.
Furlan K, Saeed-Vafa D, Mathew T, Saller J, Tabbara S, Boyle T, et al.
Head Neck Pathol
. 2024 Feb;
18(1):11.
PMID: 38393464
Background: Metastatic carcinoma of unknown primary origin to the head and neck lymph nodes (HNCUP) engenders unique diagnostic considerations. In many cases, the detection of a high-risk human papillomavirus (HR-HPV)...
3.
Nasir A, Ahmed M, Saller J, Henderson-Jackson E, Malafa M, Yeatman T, et al.
Cancer Genomics Proteomics
. 2023 Oct;
20(6):522-530.
PMID: 37889062
Background/aim: P21 is a cyclin-dependent kinase inhibitor regulating the cell cycle as a tumor suppressor. Using a p21 immunohistochemistry (IHC) assay, we compared tumor p21 levels with conventional clinico-pathological criteria...
4.
Saller J, Haider M, Al-Diffalha S, Coppola D
Anticancer Res
. 2022 Feb;
42(3):1381-1396.
PMID: 35220231
Background/aim: Cancer of unknown primary (CUP), representing 3-5% of all newly diagnosed cancers in the United States, is a presumptive, non-definitive diagnosis rendered when a primary tumor site cannot be...
5.
Saller J, Mora L, Nasir A, Mayer Z, Shahid M, Coppola D
Cancer Genomics Proteomics
. 2022 Feb;
19(2):145-150.
PMID: 35181584
Background/aim: Cancers with a microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status respond to immune checkpoint inhibition (ICI). Regardless of the tumor type, MSI-H/dMMR status is a reliable biomarker...
6.
Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller J, Smith M, et al.
Mol Cancer Res
. 2022 Jan;
20(4):542-555.
PMID: 35022314
Implications: Our study defines mechanisms of action of AXL in lung cancers which can be used to establish assays to measure drug targetable active AXL complexes in patient tissues and...
7.
Saller J, Boyle T
Cold Spring Harb Perspect Med
. 2021 Nov;
12(3).
PMID: 34751163
This overview of the molecular pathology of lung cancer includes a review of the most salient molecular alterations of the genome, transcriptome, and the epigenome. The insights provided by the...
8.
Creelan B, Wang C, Teer J, Toloza E, Yao J, Kim S, et al.
Nat Med
. 2021 Aug;
27(8):1410-1418.
PMID: 34385708
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase...
9.
Stewart P, Welsh E, Fang B, Izumi V, Mesa T, Zhang C, et al.
Methods Mol Biol
. 2020 Sep;
2194:187-221.
PMID: 32926368
Highly collaborative scientists are often called on to extend their expertise to different types of projects and to expand the scope and scale of projects well beyond their previous experience....
10.
Kang Y, Falzone A, Liu M, Gonzalez-Sanchez P, Choi B, Coloff J, et al.
Cancer Metab
. 2020 Jun;
8:6.
PMID: 32549981
Background: d-3-phosphoglycerate dehydrogenase (PHGDH), which encodes the first enzyme in serine biosynthesis, is overexpressed in human cancers and has been proposed as a drug target. However, whether PHGDH is critical...